QuantaBio
Private Company
Total funding raised: $15M
Overview
Founded in 2005 and headquartered in Beverly, Massachusetts, QuantaBio has established itself as a key provider of specialized reagents for PCR, qPCR, and NGS workflows. The company's core innovation lies in its proprietary enzyme engineering, which produces robust mixes that neutralize common PCR inhibitors, offering significant workflow advantages. With a focus on reducing costs and improving performance in genomics, QuantaBio serves a global customer base across academia, diagnostics, and agricultural genomics. It operates as a private, revenue-generating company with a platform-agnostic reagent business model.
Technology Platform
Proprietary enzyme engineering and formulation for creating inhibitor-resistant "ToughMix" reagents for PCR, qPCR, and NGS library preparation, enabling direct amplification from complex samples.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
QuantaBio competes in a crowded field dominated by large players like Thermo Fisher Scientific, Qiagen, and Bio-Rad. It differentiates through its specialized focus on inhibitor-tolerant chemistry for difficult samples, a niche where it competes with companies like Takara Bio and specialized divisions of larger firms. Its sparQ NGS line competes directly with Illumina's own library prep kits and those from New England Biolabs.